“Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated With Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine, vol. 3, no. 2, Mar. 2019, p. 175, https://doi.org/10.25251/skin.3.2.15.